Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation.

Chen XQ, Fang F, Florio JB, Rockenstein E, Masliah E, Mobley WC, Rissman RA, Wu C.

Traffic. 2018 Nov;19(11):840-853. doi: 10.1111/tra.12610. Epub 2018 Sep 12.

PMID:
30120810
2.

Trends in Readmission Rates, Hospital Charges, and Mortality for Patients With Chronic Obstructive Pulmonary Disease (COPD) in Florida From 2009 to 2014.

Jiang X, Xiao H, Segal R, Mobley WC, Park H.

Clin Ther. 2018 Apr;40(4):613-626.e1. doi: 10.1016/j.clinthera.2018.03.006. Epub 2018 Mar 31.

PMID:
29609879
3.

Inhibition of RhoA reduces propofol-mediated growth cone collapse, axonal transport impairment, loss of synaptic connectivity, and behavioural deficits.

Pearn ML, Schilling JM, Jian M, Egawa J, Wu C, Mandyam CD, Fannon-Pavlich MJ, Nguyen U, Bertoglio J, Kodama M, Mahata SK, DerMardirossian C, Lemkuil BP, Han R, Mobley WC, Patel HH, Patel PM, Head BP.

Br J Anaesth. 2018 Apr;120(4):745-760. doi: 10.1016/j.bja.2017.12.033. Epub 2018 Feb 15.

PMID:
29576115
4.

Swedish Nerve Growth Factor Mutation (NGFR100W) Defines a Role for TrkA and p75NTR in Nociception.

Sung K, Ferrari LF, Yang W, Chung C, Zhao X, Gu Y, Lin S, Zhang K, Cui B, Pearn ML, Maloney MT, Mobley WC, Levine JD, Wu C.

J Neurosci. 2018 Apr 4;38(14):3394-3413. doi: 10.1523/JNEUROSCI.1686-17.2018. Epub 2018 Feb 26.

5.

Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome.

Chen XQ, Sawa M, Mobley WC.

Free Radic Biol Med. 2018 Jan;114:52-61. doi: 10.1016/j.freeradbiomed.2017.10.341. Epub 2017 Oct 12. Review.

PMID:
29031834
6.

PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).

Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC; Down Syndrome Biomarker Initiative and the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;60(2):439-450. doi: 10.3233/JAD-170390.

PMID:
28946567
7.

Dissociation of Down syndrome and Alzheimer's disease effects with imaging.

Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS.

Alzheimers Dement (N Y). 2016 Jun;2(2):69-81. doi: 10.1016/j.trci.2016.02.004.

8.

Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.

Wagner SL, Rynearson KD, Duddy SK, Zhang C, Nguyen PD, Becker A, Vo U, Masliah D, Monte L, Klee JB, Echmalian CM, Xia W, Quinti L, Johnson G, Lin JH, Kim DY, Mobley WC, Rissman RA, Tanzi RE.

J Pharmacol Exp Ther. 2017 Jul;362(1):31-44. doi: 10.1124/jpet.117.240861. Epub 2017 Apr 17.

9.

Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Kleschevnikov AM, Yu J, Kim J, Lysenko LV, Zeng Z, Yu YE, Mobley WC.

Neurobiol Dis. 2017 Jul;103:1-10. doi: 10.1016/j.nbd.2017.03.009. Epub 2017 Mar 22.

10.

Mouse-based genetic modeling and analysis of Down syndrome.

Xing Z, Li Y, Pao A, Bennett AS, Tycko B, Mobley WC, Yu YE.

Br Med Bull. 2016 Dec;120(1):111-122. Epub 2016 Oct 27. Review.

11.

GABAergic hyperinnervation of dentate granule cells in the Ts65Dn mouse model of down syndrome: Exploring the role of App.

Mojabi FS, Fahimi A, Moghadam S, Moghadam S, Windy McNerneny M, Ponnusamy R, Kleschevnikov A, Mobley WC, Salehi A.

Hippocampus. 2016 Dec;26(12):1641-1654. doi: 10.1002/hipo.22664. Epub 2016 Oct 24.

PMID:
27701794
12.

TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.

Zhao X, Chen XQ, Han E, Hu Y, Paik P, Ding Z, Overman J, Lau AL, Shahmoradian SH, Chiu W, Thompson LM, Wu C, Mobley WC.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5655-64. doi: 10.1073/pnas.1603020113. Epub 2016 Sep 6.

13.

A Syntenic Cross Species Aneuploidy Genetic Screen Links RCAN1 Expression to β-Cell Mitochondrial Dysfunction in Type 2 Diabetes.

Peiris H, Duffield MD, Fadista J, Jessup CF, Kashmir V, Genders AJ, McGee SL, Martin AM, Saiedi M, Morton N, Carter R, Cousin MA, Kokotos AC, Oskolkov N, Volkov P, Hough TA, Fisher EM, Tybulewicz VL, Busciglio J, Coskun PE, Becker A, Belichenko PV, Mobley WC, Ryan MT, Chan JY, Laybutt DR, Coates PT, Yang S, Ling C, Groop L, Pritchard MA, Keating DJ.

PLoS Genet. 2016 May 19;12(5):e1006033. doi: 10.1371/journal.pgen.1006033. eCollection 2016 May.

14.

Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration.

Xu W, Weissmiller AM, White JA 2nd, Fang F, Wang X, Wu Y, Pearn ML, Zhao X, Sawa M, Chen S, Gunawardena S, Ding J, Mobley WC, Wu C.

J Clin Invest. 2016 May 2;126(5):1815-33. doi: 10.1172/JCI82409. Epub 2016 Apr 11.

15.

An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.

Belichenko PV, Madani R, Rey-Bellet L, Pihlgren M, Becker A, Plassard A, Vuillermot S, Giriens V, Nosheny RL, Kleschevnikov AM, Valletta JS, Bengtsson SK, Linke GR, Maloney MT, Hickman DT, Reis P, Granet A, Mlaki D, Lopez-Deber MP, Do L, Singhal N, Masliah E, Pearn ML, Pfeifer A, Muhs A, Mobley WC.

PLoS One. 2016 Mar 29;11(3):e0152471. doi: 10.1371/journal.pone.0152471. eCollection 2016.

16.

Questioned validity of Gene Expression Dysregulated Domains in Down's Syndrome.

Do LH, Mobley WC, Singhal N.

F1000Res. 2015 Jul 17;4:269. doi: 10.12688/f1000research.6735.1. eCollection 2015.

17.

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA.

Front Behav Neurosci. 2015 Sep 14;9:239. doi: 10.3389/fnbeh.2015.00239. eCollection 2015.

18.

Genetic dissection of the Down syndrome critical region.

Jiang X, Liu C, Yu T, Zhang L, Meng K, Xing Z, Belichenko PV, Kleschevnikov AM, Pao A, Peresie J, Wie S, Mobley WC, Yu YE.

Hum Mol Genet. 2015 Nov 15;24(22):6540-51. doi: 10.1093/hmg/ddv364. Epub 2015 Sep 15.

19.

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.

Zhao Y, Tseng IC, Heyser CJ, Rockenstein E, Mante M, Adame A, Zheng Q, Huang T, Wang X, Arslan PE, Chakrabarty P, Wu C, Bu G, Mobley WC, Zhang YW, St George-Hyslop P, Masliah E, Fraser P, Xu H.

Neuron. 2015 Sep 2;87(5):963-75. doi: 10.1016/j.neuron.2015.08.020.

20.

Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues.

Belichenko PV, Kleschevnikov AM, Becker A, Wagner GE, Lysenko LV, Yu YE, Mobley WC.

PLoS One. 2015 Jul 31;10(7):e0134861. doi: 10.1371/journal.pone.0134861. eCollection 2015.

21.

Rat embryonic hippocampus and induced pluripotent stem cell derived cultured neurons recover from laser-induced subaxotomy.

Selfridge A, Hyun N, Chiang CC, Reyna SM, Weissmiller AM, Shi LZ, Preece D, Mobley WC, Berns MW.

Neurophotonics. 2015 Jan;2(1):015006. doi: 10.1117/1.NPh.2.1.015006. Epub 2015 Feb 13.

22.

Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome.

Nosheny RL, Belichenko PV, Busse BL, Weissmiller AM, Dang V, Das D, Fahimi A, Salehi A, Smith SJ, Mobley WC.

Neurobiol Dis. 2015 May;77:173-90. doi: 10.1016/j.nbd.2015.02.022. Epub 2015 Mar 6.

23.

A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP.

Weissmiller AM, Natera-Naranjo O, Reyna SM, Pearn ML, Zhao X, Nguyen P, Cheng S, Goldstein LS, Tanzi RE, Wagner SL, Mobley WC, Wu C.

PLoS One. 2015 Feb 24;10(2):e0118379. doi: 10.1371/journal.pone.0118379. eCollection 2015.

24.

Real-time imaging of axonal transport of quantum dot-labeled BDNF in primary neurons.

Zhao X, Zhou Y, Weissmiller AM, Pearn ML, Mobley WC, Wu C.

J Vis Exp. 2014 Sep 15;(91):51899. doi: 10.3791/51899.

25.

Preparation of primary neurons for visualizing neurites in a frozen-hydrated state using cryo-electron tomography.

Shahmoradian SH, Galiano MR, Wu C, Chen S, Rasband MN, Mobley WC, Chiu W.

J Vis Exp. 2014 Feb 12;(84):e50783. doi: 10.3791/50783.

26.

Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species.

Wagner SL, Zhang C, Cheng S, Nguyen P, Zhang X, Rynearson KD, Wang R, Li Y, Sisodia SS, Mobley WC, Tanzi RE.

Biochemistry. 2014 Feb 4;53(4):702-13. doi: 10.1021/bi401537v. Epub 2014 Jan 22.

27.

The challenge of connecting the dots in the B.R.A.I.N.

Devor A, Bandettini PA, Boas DA, Bower JM, Buxton RB, Cohen LB, Dale AM, Einevoll GT, Fox PT, Franceschini MA, Friston KJ, Fujimoto JG, Geyer MA, Greenberg JH, Halgren E, Hämäläinen MS, Helmchen F, Hyman BT, Jasanoff A, Jernigan TL, Judd LL, Kim SG, Kleinfeld D, Kopell NJ, Kutas M, Kwong KK, Larkum ME, Lo EH, Magistretti PJ, Mandeville JB, Masliah E, Mitra PP, Mobley WC, Moskowitz MA, Nimmerjahn A, Reynolds JH, Rosen BR, Salzberg BM, Schaffer CB, Silva GA, So PT, Spitzer NC, Tootell RB, Van Essen DC, Vanduffel W, Vinogradov SA, Wald LL, Wang LV, Weber B, Yodh AG.

Neuron. 2013 Oct 16;80(2):270-4. doi: 10.1016/j.neuron.2013.09.008.

28.

Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits.

Zhang L, Meng K, Jiang X, Liu C, Pao A, Belichenko PV, Kleschevnikov AM, Josselyn S, Liang P, Ye P, Mobley WC, Yu YE.

Hum Mol Genet. 2014 Feb 1;23(3):578-89. doi: 10.1093/hmg/ddt446. Epub 2013 Sep 16.

29.

Aging and intellectual disability: insights from mouse models of Down syndrome.

Ruparelia A, Pearn ML, Mobley WC.

Dev Disabil Res Rev. 2013;18(1):43-50. doi: 10.1002/ddrr.1127. Review.

PMID:
23949828
30.

Illicium sesquiterpenes: divergent synthetic strategy and neurotrophic activity studies.

Trzoss L, Xu J, Lacoske MH, Mobley WC, Theodorakis EA.

Chemistry. 2013 May 10;19(20):6398-408. doi: 10.1002/chem.201300198. Epub 2013 Mar 22.

31.

Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down's syndrome.

Wang X, Zhao Y, Zhang X, Badie H, Zhou Y, Mu Y, Loo LS, Cai L, Thompson RC, Yang B, Chen Y, Johnson PF, Wu C, Bu G, Mobley WC, Zhang D, Gage FH, Ranscht B, Zhang YW, Lipton SA, Hong W, Xu H.

Nat Med. 2013 Apr;19(4):473-80. doi: 10.1038/nm.3117. Epub 2013 Mar 24.

32.

NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington's Disease.

Zhang H, Petit GH, Gaughwin PM, Hansen C, Ranganathan S, Zuo X, Smith R, Roybon L, Brundin P, Mobley WC, Li JY.

J Huntingtons Dis. 2013;2(1):69-82. doi: 10.3233/JHD-120026.

PMID:
25063430
33.

Potential use of γ-secretase modulators in the treatment of Alzheimer disease.

Wagner SL, Tanzi RE, Mobley WC, Galasko D.

Arch Neurol. 2012 Oct;69(10):1255-8. Review.

34.

Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.

Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC.

J Neurosci. 2012 Jul 4;32(27):9217-27. doi: 10.1523/JNEUROSCI.1673-12.2012.

35.

Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.

Ruparelia A, Pearn ML, Mobley WC.

Curr Opin Neurobiol. 2012 Oct;22(5):880-6. doi: 10.1016/j.conb.2012.05.002. Epub 2012 May 30.

36.

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering.

Zhang L, Fu D, Belichenko PV, Liu C, Kleschevnikov AM, Pao A, Liang P, Clapcote SJ, Mobley WC, Yu YE.

Bioeng Bugs. 2012 Jan 1;3(1):8-12. doi: 10.4161/bbug.3.1.17696. Epub 2012 Jan 1.

37.

Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.

Kleschevnikov AM, Belichenko PV, Gall J, George L, Nosheny R, Maloney MT, Salehi A, Mobley WC.

Neurobiol Dis. 2012 Feb;45(2):683-91. doi: 10.1016/j.nbd.2011.10.009. Epub 2011 Oct 17.

38.

Mouse models for Down syndrome-associated developmental cognitive disabilities.

Liu C, Belichenko PV, Zhang L, Fu D, Kleschevnikov AM, Baldini A, Antonarakis SE, Mobley WC, Yu YE.

Dev Neurosci. 2011;33(5):404-13. doi: 10.1159/000329422. Epub 2011 Aug 25. Review.

39.

Enantioselective synthesis of (-)-jiadifenin, a potent neurotrophic modulator.

Trzoss L, Xu J, Lacoske MH, Mobley WC, Theodorakis EA.

Org Lett. 2011 Sep 2;13(17):4554-7. doi: 10.1021/ol201742j. Epub 2011 Aug 3.

40.

Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.

Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, Saw N, Priestley M, Tsien RW, Mobley WC, Shamloo M.

Neurobiol Dis. 2011 Aug;43(2):397-413. doi: 10.1016/j.nbd.2011.04.011. Epub 2011 Apr 17.

41.

Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease.

Rissman RA, Mobley WC.

J Neurochem. 2011 May;117(4):613-22. doi: 10.1111/j.1471-4159.2011.07237.x. Epub 2011 Mar 28. Review.

42.

Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice.

Yu T, Liu C, Belichenko P, Clapcote SJ, Li S, Pao A, Kleschevnikov A, Bechard AR, Asrar S, Chen R, Fan N, Zhou Z, Jia Z, Chen C, Roder JC, Liu B, Baldini A, Mobley WC, Yu YE.

Brain Res. 2010 Dec 17;1366:162-71. doi: 10.1016/j.brainres.2010.09.107. Epub 2010 Oct 26.

43.

Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease.

Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE, Wagner SL.

Neuron. 2010 Sep 9;67(5):769-80. doi: 10.1016/j.neuron.2010.08.018.

44.

Deficiencies in the region syntenic to human 21q22.3 cause cognitive deficits in mice.

Yu T, Clapcote SJ, Li Z, Liu C, Pao A, Bechard AR, Carattini-Rivera S, Matsui S, Roder JC, Baldini A, Mobley WC, Bradley A, Yu YE.

Mamm Genome. 2010 Jun;21(5-6):258-67. doi: 10.1007/s00335-010-9262-x. Epub 2010 May 29.

45.

Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome.

Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC.

Sci Transl Med. 2009 Nov 18;1(7):7ra17. doi: 10.1126/scitranslmed.3000258.

46.

The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome.

Mégarbané A, Ravel A, Mircher C, Sturtz F, Grattau Y, Rethoré MO, Delabar JM, Mobley WC.

Genet Med. 2009 Sep;11(9):611-6. doi: 10.1097/GIM.0b013e3181b2e34c. Review.

PMID:
19636252
47.

The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.

Belichenko NP, Belichenko PV, Kleschevnikov AM, Salehi A, Reeves RH, Mobley WC.

J Neurosci. 2009 May 6;29(18):5938-48. doi: 10.1523/JNEUROSCI.1547-09.2009.

48.

Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks.

Belichenko PV, Wright EE, Belichenko NP, Masliah E, Li HH, Mobley WC, Francke U.

J Comp Neurol. 2009 May 20;514(3):240-58. doi: 10.1002/cne.22009.

PMID:
19296534
49.

Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation.

Belichenko NP, Belichenko PV, Mobley WC.

Neurobiol Dis. 2009 Apr;34(1):71-7. doi: 10.1016/j.nbd.2008.12.016. Epub 2009 Jan 8.

PMID:
19167498
50.

Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome.

Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, Salehi A, Mobley WC.

J Comp Neurol. 2009 Feb 1;512(4):453-66. doi: 10.1002/cne.21895.

PMID:
19034952

Supplemental Content

Loading ...
Support Center